Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.34 |
| ▸ | CFD | P00746 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22654944 | 1.00 | DPP4 (0.37) | DPP4MAPTHCRTR1HCRTR2CFD | |
| SCHEMBL22670584 | 0.84 | LMNA (0.36) | DPP4MAPTPOLBLMNAHTT | |
| SCHEMBL22671985 | 0.84 | LMNA (0.36) | DPP4MAPTPOLBLMNAHTT | |
| SCHEMBL29565667 | 0.84 | LMNA (0.36) | DPP4MAPTPOLBLMNAHTT | |
| SCHEMBL29565864 | 0.84 | LMNA (0.36) | DPP4MAPTPOLBLMNAHTT | |
| SCHEMBL23523581 | 0.73 | FAAH (0.37) | MAPTPOLBLMNAHTTALDH1A1 | |
| SCHEMBL23523585 | 0.73 | FAAH (0.37) | MAPTPOLBLMNAHTTALDH1A1 | |
| SCHEMBL23523583 | 0.73 | FAAH (0.37) | MAPTPOLBLMNAHTTALDH1A1 | |
| SCHEMBL20956856 | 0.68 | HDAC1 (0.40) | DPP4CFD | |
| SCHEMBL20956830 | 0.68 | HDAC1 (0.40) | DPP4CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2022-02-22 | — | — | US | disclosed |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2021-12-28 | — | — | US | disclosed |
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361898-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | DPP4 326/4885MAPT 913/4885HCRTR1 370/4885 |
| US-11254653-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | DPP4 326/4885MAPT 913/4885HCRTR1 370/4885 |
| US-20200361899-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | DPP4 326/4885MAPT 913/4885HCRTR1 370/4885 |
| US-11208399-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | DPP4 326/4885MAPT 913/4885HCRTR1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.